Opinion | Dr. Prasad, the FDA’s Grim Reaper
NegativeTechnology

The recent decision by Dr. Prasad and the FDA to block a crucial therapy for late-stage melanoma has raised serious concerns, as it could lead to the loss of many lives. This decision not only affects patients desperately seeking treatment but also highlights the ongoing debate about regulatory practices in healthcare. The implications of such a move are profound, as it underscores the tension between safety regulations and the urgent need for effective cancer therapies.
— Curated by the World Pulse Now AI Editorial System